The lancet oncology
-
The lancet oncology · Sep 2014
Multicenter StudyAdapted paediatric regimen benefits adults with ALL.
-
The lancet oncology · Sep 2014
Randomized Controlled Trial Multicenter Study Comparative StudyFOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (FOLFIRI) is unknown. We aimed to compare these agents in patients with KRAS (exon 2) codon 12/13 wild-type metastatic colorectal cancer. ⋯ Merck KGaA.
-
The lancet oncology · Sep 2014
Randomized Controlled Trial Multicenter Study Comparative StudyIntegrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer.
The management of depression in patients with poor prognosis cancers, such as lung cancer, creates specific challenges. We aimed to assess the efficacy of an integrated treatment programme for major depression in patients with lung cancer compared with usual care. ⋯ Cancer Research UK and Chief Scientist Office of the Scottish Government.
-
The lancet oncology · Sep 2014
Randomized Controlled Trial Multicenter StudyLanreotide delays progression of neuroendocrine tumours.
-
The lancet oncology · Sep 2014
Randomized Controlled Trial Multicenter Study Comparative StudySunitinib still fi rst-line therapy for metastatic renal cancer.